ILMN · Illumina, Inc.
$269.42
+0.01% last session
End-of-day data · close of 2026-10-23
Market cap
$41B
Enterprise value
$42B
Trailing P/E
50.3
Forward P/E
44.0
Dividend yield
0.0%
Beta
1.42
Avg volume
3M
Employees
9K
Daily Change %
0.01%
5 Days Change
2.61%
10 Days Change
-0.66%
30 Days Change
5.49%
60 Days Change
20.69%
Month to Day Change
1.38%
Year to Day Change
105.40%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ILMN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
Barclays
Underweight$200
-25.8% vs priceRBC Capital
Outperform$310
+15.1% vs priceUBS
Buy$260
-3.5% vs priceCitigroup
Sell$113
-58.1% vs priceJP Morgan
Overweight$230
-14.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | Maintains | Hold | $205 → $300 |
| 2026-10-13 | TD Cowen | Maintains | Hold | $210 → $270 |
| 2026-10-07 | Barclays | Maintains | Underweight | $160 → $200 |
| 2026-10-05 | RBC Capital | Maintains | Outperform | $230 → $310 |
| 2026-10-01 | Guggenheim | Maintains | Buy | $226 → $305 |
| 2026-09-29 | Leerink Partners | Maintains | Outperform | $220 → $300 |
| 2026-09-28 | Piper Sandler | Maintains | Overweight | $225 → $305 |
| 2026-09-09 | UBS | Upgrade | Neutral → Buy | $135 → $260 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 11.4% above the 50-day MA ($241.80).
- bullish: Price vs 200-day MA: Trading 55.8% above the 200-day MA ($172.89).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-2.35) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($95.03) and high ($293.69).
ILMN Price Chart
Loading chart for ILMN…
Fundamentals
About Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
MTD
Mettler-Toledo International, I
$33B 20.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.